FDA approves Zostavax vaccine to prevent shingles in individuals 50 to 59 years of age

Sent from my BlackBerry® wireless handheld

---

From: Gamal Alhadad <fbmessage+o=lvclp1@facebookmail.com>

Date: Mon, 28 Mar 2011 01:08:43 -0700

To: Ayman Moftah<aymanmoftah2000@yahoo.com>

ReplyTo: قم بالرد للتعلي ق <g+43ig64o000000adu7s5001d95l9n6f30019y2awmk4r1qv3o@groups.facebook.com>

Subject: [جروب الطب فى خ دمة الشعب] The Food and Drug A dministration ( FDA) approved.. .

Gamal Alhadad ‏تم النشر في جروب الطب فى خدمة الشعب‏‏. Gamal Alhadad 28 مارس 10:08 صباحاً The Food and Drug Administration (FDA) approved the use of Zostavax, a live attenuated virus vaccine, for the prevention of shingles الهربس العصبى in individuals 50 to 59 years of age. Zostavax is already approved for use in individuals 60 years of age and older. FDA approves Zostavax vaccine to prevent shingles in individuals 50 to 59 years of age www.fda.gov The Food and Drug Administration (FDA) today approved the use of Zostavax, a live attenuated virus vaccine, for the prevention of shingles in individuals 50 to 59 years of age. Zostavax is already approved for use in individuals 60 years of age and older. عرض المنشور في فيس بوك · تعديل إعدادات البريد الإلكتروني · الرد على هذا البريد الإلكتروني لإضافة تعليق.